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demonstrate cartilage destructive properties as expressed by an
increased release and a decreased synthesis rate and content
of cartilage proteoglycans. The synovial tissue destructive prop-
erties increase with time after the experimental haemorrhage
(+168%/+260%; -76%/-83%; -18%/-32% respectively, for 24/48
hours).
Conclusions: Although intra-articular blood is cleared within 2
days from the canine knee joint (<10% left), adverse effects
on cartilage and synovium are already initiated within 1 day, and
they are more severe 2 days after the experimental haemorrhage.
Although these are only short-term effects in the canine joint, it
is clear that only a small amount of blood in a joint for a short
period of time can result in a condition signiﬁcantly compromising
the joint.
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Purpose: Recently, it has been demonstrated that lectin-like
ox-LDL receptor-1 (LOX-1) is expressed on chondrocytes and
suggested in vitro and vivo that its ligand ox-LDL play some
role in degeneration of articular cartilage. To investigate whether
oxidized low-density lipoprotein (ox-LDL) binding to lectin-like
ox-LDL receptor 1 (LOX-1) enhances monocyte chemoattrac-
tant protein 1 (MCP-1) expression in cultured human articular
chondrocytes (HACs). Furthermore, to ascertain whether the
ox-LDL-induced MCP-1 upregulation is mediated by NF-kappaB
activation.
Methods: The time course and dose response of MCP-1 mRNA
expression and MCP-1 protein release into medium following
ox-LDL stimulation were investigated using RT-PCR and ELISA,
respectively. HACs were also preincubated with anti-human LOX-
1 mAb (TS92) and speciﬁc NF-kappaB inhibitors (BAY11-7082,
MG132, and SN50). Whole cell extracts from HACs treated
for the indicated periods with ox-LDL and preincubated with
the TS92 were prepared, and NF-kappaB activation (p65 DNA
binding activity) following ox-LDL stimulation was investigated by
ELISA.
Results: LOX-1 mRNA expression in HACs was conﬁrmed by
RT-PCR. Ox-LDL signiﬁcantly increased MCP-1 mRNA and pro-
tein expression levels in a time- and dose-dependent manner,
which was suppressed markedly by pretreatment with TS92
and NF-kappaB inhibitors (Fig. 1). Ox-LDL stimulation activated
NF-kappaB in HACs in a dose-dependent manner, which was
suppressed by TS92 pretreatment (Fig. 2). NF-kappaB inhibitors
signiﬁcantly suppressed ox-LDL-induced MCP-1 expression.
Conclusions: It has been reported that chemokines produced by
chondrocytes and chemokine receptors expressed on chondro-
cytes play an important role in pathogenesis of arthritis through
intra-articular recruitment of monocytes/macrophages and the
activation of matrix degrading enzymes. Our results suggest that
the ox-LDL binding to LOX-1 enhances MCP-1 expression in
human articular chondrocytes through activation of NF-kappaB
and supports the hypothesis that ox-LDL deposition in cartilage
and its receptor LOX-1 expression on chondrocytes are involved
in degeneration of cartilage in osteoarthritis and rheumatoid
arthritis.
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Purpose: It has been proposed that diacerhein acts as a slow-
acting, symptom-modifying and perhaps as a disease-structure
modifying drug in the treatment of osteoarthritis (OA), although its
effects on cartilage and synovial catabolic program remain poorly
studied. This work was designed to simultaneously study the
effects of diacerhein and that of conventional symptomatic drugs,
like NSAIDs, on the synthesis of inﬂammation and structural
mediators in OA chondrocytes and synoviocytes in culture.
Methods: Chondrocytes and synoviocytes were obtained from
joint specimens of OA patients who underwent total knee re-
placement surgery. We used quiescent cells stimulated with
10 U/ML IL-1β, and studied the effects of diacerhein (10-5M),
celecoxib (CBX, 10-6M), diclofenac (DCF, 10-6M), meloxicam
(MXC, 10-6M) and indomethacin (IND, 10-6M) in the release of
prostaglandin (PG) E2 and nitric oxide (NO), the expression of
cyclooxigenase (COX)-2, the accumulation of metalloproteinase
(MMP)-1 and MMP-13, and the activation of the nuclear fac-
tor kappa B (NF-kB). All drugs were tested at the mean peak
plasma concentration (Cmax) observed after oral administration
of a therapeutic dose.
Results: The activation of NF-kB binding induced by IL-1 was
inhibited by diacerhein, both in chondrocytes and synoviocytes.
All of the NSAIDs used in these experiments also inhibited the
activation of NF-kB induced by IL-1, although IND only showed
this effect on chondrocytes. Regarding the prostaglandin system,
we showed that diacerhein did not revert the increase in COX-2
